420 related articles for article (PubMed ID: 25447947)
21. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
[No Abstract] [Full Text] [Related]
22. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
[TBL] [Abstract][Full Text] [Related]
23. Update in Cystic Fibrosis 2014.
Ong T; Ramsey BW
Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
[No Abstract] [Full Text] [Related]
24. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
25. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
[No Abstract] [Full Text] [Related]
26. Breathing easier with combinations.
Azvolinsky A
Nat Biotechnol; 2015 Nov; 33(11):1128-30. PubMed ID: 26544137
[No Abstract] [Full Text] [Related]
27. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Mitchell RM; Jones AM; Barry PJ
Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
[TBL] [Abstract][Full Text] [Related]
28. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
[No Abstract] [Full Text] [Related]
29. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
[TBL] [Abstract][Full Text] [Related]
30. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
Elborn JS; Ramsey B; Wainwright C; Boyle M
Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
[No Abstract] [Full Text] [Related]
31. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
[No Abstract] [Full Text] [Related]
32. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
33. New and emerging targeted therapies for cystic fibrosis.
Quon BS; Rowe SM
BMJ; 2016 Mar; 352():i859. PubMed ID: 27030675
[TBL] [Abstract][Full Text] [Related]
34. New treatments targeting the basic defects in cystic fibrosis.
Fajac I; Wainwright CE
Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
[TBL] [Abstract][Full Text] [Related]
35. [Therapeutic update in cystic fibrosis].
Durupt S; Nove Josserand R; Durieu I
Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546
[TBL] [Abstract][Full Text] [Related]
36. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.
Jennings MT; Flume PA
Ann Am Thorac Soc; 2018 Aug; 15(8):897-902. PubMed ID: 29812963
[TBL] [Abstract][Full Text] [Related]
37. Pulmonology: CFTR modulators for cystic fibrosis.
Bertoncini E; Colomb-Lippa D
JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
[No Abstract] [Full Text] [Related]
38. Update on new pulmonary therapies.
Retsch-Bogart GZ
Curr Opin Pulm Med; 2009 Nov; 15(6):604-10. PubMed ID: 19696677
[TBL] [Abstract][Full Text] [Related]
39. Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Real-World Evidence Highlights Need for Worldwide Access.
Barry PJ; Jones AM
Ann Am Thorac Soc; 2024 Jul; 21(7):1003-1004. PubMed ID: 38949605
[No Abstract] [Full Text] [Related]
40. Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
VanDevanter DR; Mayer-Hamblett N
Curr Opin Pulm Med; 2017 Nov; 23(6):530-535. PubMed ID: 28708817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
